Ivosidenib Deemed Safe, Effective in AML.
A phase I study suggests that ivosidenib can induce remission in patients with relapsed or refractory acute myeloid leukemia characterized by IDH1 mutations. The drug spurred complete remission or complete remission with partial hematologic recovery in 30.4% of patients. The most common side effects of at least grade 3 were prolonged QT interval and IDH differentiation syndrome.